This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Sept. 15, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the UBS Global Life Sciences Conference on
Tuesday, September 20, 2011 at
4:30 p.m. EDT (
1:30 p.m. PDT). The conference is being held at the Grand Hyatt in
New York. Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, setrobuvir and ANA773.
Dr. Worland will also present at the JMP Securities Healthcare Conference on
Tuesday, September 27, 2011 at
2:00 p.m. EDT (
11:00 a.m. PDT). The conference is being held at the St. Regis Hotel in
Each presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at
www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to each presentation to download or install any necessary software. A replay of the presentations will be available approximately one hour after the live webcasts conclude and will be available through
October 4, 2011 and
October 11, 2011, respectively.
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. Anadys is conducting a Phase IIb study of setrobuvir, the Company's DAA, added to pegylated interferon and ribavirin for the treatment of hepatitis C. The Company is also developing ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C and plans to initiate a Phase IIa study shortly.